Frequently Asked Questions
I’m concerned about the side effects of FASLODEX 500 mg versus 250 mg. Will doubling the dose double the side effects?
A: Although the dose was double, the Study 1 (CONFIRM) trial demonstrated that FASLODEX 500 mg had a safety profile comparable to 250 mg in terms of the most commonly reported adverse events.2 In the Study 1 (CONFIRM) trial, the most common adverse reactions reported for patients treated with FASLODEX 500 mg were injection site pain (11.6% of patients), nausea (9.7% of patients) and bone pain (9.4% of patients); the most frequently reported adverse reactions in the FASLODEX 250 mg group were nausea (13.6% of patients), back pain (10.7% of patients), and injection site pain (9.1% of patients).1
Back to top
How can I get my questions about reimbursement answered?
A: You can call our AstraZeneca Reimbursement Services, a team of reimbursement specialists, to assist your office with coding, coverage, and payment inquiries. The phone number is 1-877-674-7140, Monday through Friday, 8:00 AM to 6:00 PM ET.
Back to top
What is the NDC code for ordering?
A: You may order the FASLODEX 500-mg (2 x 5-mL) pack through your wholesaler. The NDC code is NDC 0310-0720-10.1 If you have questions and would like to have an AstraZeneca representative contact you, you may Request a Rep.
Back to top
How is FASLODEX 500 mg supplied?
A: FASLODEX is now supplied as two 5-mL clear neutral glass barrels, each containing 250 mg/5 mL of fulvestrant solution for intramuscular injection and fitted with a tamper-evident closure.1 The syringes are presented in a tray with a polystyrene plunger rod and safety needles (SafetyGlide™) for connection to the barrel.1
Back to top
If I use a 250-mg dose for a patient with moderate hepatic impairment, how should I store the FASLODEX 2 x 5 mL pack?
A: Immediately store the other 5-mL syringe as directed in the Prescribing Information— REFRIGERATE, 2°-8°C (36°-46°F). TO PROTECT FROM LIGHT, STORE IN ORIGINAL CARTON.1
Back to top
FASLODEX is indicated for the treatment of hormone receptor-positive metastatic breast cancer in postmenopausal women with disease
progression following antiestrogen therapy.
IMPORTANT SAFETY INFORMATION:
FASLODEX is contraindicated in patients with known hypersensitivity to the drug or to
any of its components. Hypersensitivity reactions, including urticaria and angioedema have been reported in association with FASLODEX.
Click Here for Additional Safety Information
OnCue - News for
oncology professionals
Regularly updated articles cover a range of topics including treatment information, oncology conferences details, and patient resources.
Visit OnCueFeed.com
Get Connected
Request to have an AstraZeneca representative contact you.
Request a Rep